A detailed history of Principal Securities, Inc. transactions in Genfit S.A. stock. As of the latest transaction made, Principal Securities, Inc. holds 24 shares of GNFT stock, worth $90. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24
Holding current value
$90
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 11, 2025

BUY
$2.72 - $4.6 $65 - $110
24 New
24 $89,000

Others Institutions Holding GNFT

About Genfit S.A.


  • Ticker GNFT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,815,500
  • Market Cap $189M
  • Description
  • Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagno...
More about GNFT
Track This Portfolio

Track Principal Securities, Inc. Portfolio

Follow Principal Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Principal Securities, Inc. with notifications on news.